Genomtec S.A. (GMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genomtec S.A. (GMT) has a cash flow conversion efficiency ratio of -0.262x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.84 Million ≈ $-506.39K USD) by net assets (zł7.02 Million ≈ $1.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Genomtec S.A.'s balance sheet to measure how much of total assets are equity-financed.
Genomtec S.A. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Genomtec S.A. (GMT) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Genomtec S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genomtec S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SYZYGY AG
XETRA:SYZ
|
-0.025x |
|
Czerwona Torebka
WAR:CZT
|
-0.081x |
|
Sycal Ventures Bhd
KLSE:9717
|
0.031x |
|
Delta Resources Ltd
V:DLTA
|
-2.853x |
|
Almadex Minerals Ltd
V:DEX
|
-0.024x |
|
Apimeds Pharmaceuticals US, Inc.
NYSE MKT:APUS
|
-0.212x |
|
RNI Negócios Imobiliários S.A
SA:RDNI3
|
-0.026x |
|
Australian Rare EARTHS Ltd
AU:AR3
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Genomtec S.A. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Genomtec S.A. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see GMT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł7.60 Million ≈ $2.09 Million |
zł-6.72 Million ≈ $-1.85 Million |
-0.884x | +7.74% |
| 2023-12-31 | zł8.30 Million ≈ $2.28 Million |
zł-7.95 Million ≈ $-2.19 Million |
-0.958x | -24.64% |
| 2022-12-31 | zł4.93 Million ≈ $1.36 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.768x | +89.74% |
| 2021-12-31 | zł738.00K ≈ $203.11K |
zł-5.53 Million ≈ $-1.52 Million |
-7.491x | -2155.20% |
| 2020-12-31 | zł7.57 Million ≈ $2.08 Million |
zł-2.52 Million ≈ $-692.16K |
-0.332x | +78.32% |
| 2019-12-31 | zł1.11 Million ≈ $304.34K |
zł-1.69 Million ≈ $-466.31K |
-1.532x | -- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more